JULY 15, 2021 – uMotif, experts in patient-centered clinical solutions, has today announced its collaboration with Xperiome, a global healthtech company specialising in rare disease. The partnership will bring value to both life science companies conducting clinical trials and the patients participating in them, offering a new approach to patient recruitment through a community of motivated, research-ready patients and an industry-leading engagement platform to drive retention.

Clinical trial recruitment can take years, and globally, more than 85% of clinical trials fail to enroll on time. uMotif and Xperiome are joining forces to address the pain points that contribute to these delays, changing the paradigm in clinical trial recruitment by providing sponsors with the capabilities to match the right patients to the right studies, at the right time. Specifically, the partnership will leverage Xperiome’s knowledge bank for the lived experience of rare disease to build a deep understanding of hard-to-reach populations. Xperiome combines these insights with a specialized matching engine to connect research-ready members to clinical and real-world study opportunities. Then, once enrolled, uMotif’s patient-engagement app will capture large volumes of high-quality ePRO, eDiary and symptom data in real-time throughout the duration of a clinical study. The easy-to-use uMotif app empowers patients to manage and collect their own data, increasing participants’ engagement in clinical research and understanding of their symptoms and behavior among trial sponsors.

Bruce Hellman, uMotif’s CEO, said, “Having access to reliable patient data during clinical trials is crucial and it requires effective patient recruitment and engagement strategies. Xperiome and uMotif share a commitment to eliminating the friction in clinical trial enrollment, reducing the burden on both sites and participating patients. Our partnership is designed with patients in mind to help sponsors and research professionals capture the best quality data in a way that suits study participants. It’s a win-win for all stakeholders and has the potential to aid in accelerating the delivery of vital therapies to patients who need them.”

Jeremy Edwards, Xperiome’s CEO, said, “Finding and retaining eligible patients for trials is a significant challenge for pharma, especially in orphan drug research where populations are hard to reach and participation in research can add significant burdens for patients and their families. We are committed to providing more opportunity for rare disease patients to participate in clinical studies and our partnership with uMotif will deliver a better trial experience once enrolled. By working together, we will provide an end-to-end patient-focused solution that connects patients to research and supports them throughout their clinical trial journey.”

About uMotif

uMotif's mission is to put patients at the centre of clinical research. Designed with patients for patients, the uMotif patient-centric eClinical platform powers site-based to fully decentralised clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture eConsent and large volumes of ePRO, symptom, and wearable device data. To learn more visit umotif.com and follow-us via Linkedin.

About Xperiome

Xperiome is a global healthtech company that helps pharma get to know rare disease patients and their conditions faster by delivering deep insights into the patient experience. We have created Raremark as the place for the lived experience of rare disease. Raremark supports every stage of a patient's health odyssey: a community to crowdsource wisdom, a library to catalog the lived experience, and a matching engine to find research opportunities. This data-driven knowledge bank of the rare experience allows us to match research-ready members to clinical and real-world studies, faster and smarter than ever before. Learn more about Xperiome and follow Xperiome on Twitter, LinkedIn, and Facebook.

Press Contacts

PR@umotif.com

Contact@xperiome.com